Nektar Therapeutics (NKTR)
| Market Cap | 2.02B |
| Revenue (ttm) | 100.36M |
| Net Income (ttm) | -495.40M |
| Shares Out | 184.56M |
| EPS (ttm) | -2.72 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,641,313 |
| Open | 11.58 |
| Previous Close | 11.78 |
| Day's Range | 10.91 - 11.90 |
| 52-Week Range | 10.59 - 26.75 |
| Beta | 1.22 |
| Analysts | Buy |
| Price Target | 25.15 (+129.7%) |
| Earnings Date | n/a |
About NKTR
Nektar Therapeutics operates as a biopharmaceutical company. The company researches and develops pipeline of investigational medicines in oncology, immunology, and virology, as well as a portfolio of approved partnered medicines. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, and adjuvant melanoma; phase 2 clinical trial for the treatment of renal cell carcinoma and ...
Financial Performance
Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for NKTR stock is "Buy." The 12-month stock price forecast is 25.15, which is an increase of 129.68% from the latest price.
News
Nektar Therapeutics' President and CEO, Howard Robin, to Present at the 40th Annual J.P. Morgan Virtual Healthcare Co...
SAN FRANCISCO, Jan. 5, 2022 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer, Howard Robin, is scheduled to present at the upcoming 40th Annual J.P. Morgan Virtu...
Is the Options Market Predicting a Spike in Nektar Therapeutics (NKTR) Stock?
Investors need to pay close attention to Nektar Therapeutics (NKTR) stock based on the movements in the options market lately.
Nektar Therapeutics Announces Phase 1b Data for Novel T Regulatory Cell Stimulator NKTR-358 (LY3471851) in Patients w...
SAN FRANCISCO, Dec. 15, 2021 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that its partner Eli Lilly & Company presented preliminary results from a Lilly-sponsored Phase 1b proof-o...
Nektar Therapeutics Presents Clinical Data for NKTR-255 in Patients with Relapsed/Refractory Hematologic Malignancies...
SAN FRANCISCO, Dec. 13, 2021 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced two data presentations from the dose-escalation portion of its ongoing Phase 1 study of NKTR-255 in patients with...
Nektar Therapeutics Announces Data Presentations for its Immuno-Oncology Programs at the European Society for Medical...
SAN FRANCISCO, Nov. 30, 2021 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) announced today that it will present data at two upcoming medical meetings for two of its cytokine immuno-oncology program...
Nektar Therapeutics Strengthens Board of Directors with Appointment of Diana M. Brainard, M.D.
SAN FRANCISCO, Nov. 15, 2021 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced it has appointed Diana M. Brainard, M.D.
Nektar Therapeutics Announces Data Presentations for Its Immuno-Oncology Pipeline at the 2021 Society for Immunothera...
SAN FRANCISCO, Nov. 12, 2021 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced three data presentations for its I-O pipeline at the 2021 Society for Immunotherapy of Cancer (SITC) Annua...
Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors with Cancer Specialist During 2021 Socie...
SAN FRANCISCO, Nov. 9, 2021 /PRNewswire/ -- Nektar Therapeutics (NASDAQ:NKTR) announced today that it will host a webcast analyst and investor conference call with a cancer specialist and Nektar managem...
Why Nektar Therapeutics Stock Plunged Today
The company's Q3 revenue was lower than expected.
Nektar (NKTR) Q3 Earnings Top, Pipeline Remains On Track
Nektar (NKTR) reports mixed third-quarter 2021 results. The company remains on track to report top-line data from three registrational studies on bempegaldesleukin in the first half of 2022.
Nektar Therapeutics (NKTR) Reports Q3 Loss, Misses Revenue Estimates
Nektar (NKTR) delivered earnings and revenue surprises of 12.50% and -16.57%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Nektar Therapeutics Reports Third Quarter 2021 Financial Results
SAN FRANCISCO, Nov. 4, 2021 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the third quarter ended September 30, 2021. Cash and investments in marketable securit...
Nektar to Announce Financial Results for the Third Quarter 2021 on Thursday, November 4, 2021, After Close of U.S.-Ba...
SAN FRANCISCO, Oct. 26, 2021 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the third quarter 2021 on Thursday, November 4, 2021, after the close of U.S.-base...
Nektar (NKTR) Signs Deals With Pfizer, Merck KGaA for NKTR-255
Nektar (NKTR) signs a collaboration deal with Pfizer and Merck KGaA to develop a combination of its NKTR-255 with the latter's Bavencio for treating urothelial carcinoma.
Nektar, Merck Germany, Pfizer Join Forces For Mid-Stage Bladder Cancer Study
Nektar Therapeutics Inc (NASDAQ: NKTR) has entered into a new oncology clinical collaboration with Merck KGaA (OTC: MKGAF) and Pfizer Inc (NYSE: PFE) to evaluate the maintenance regimen of NKTR-255 in c...
Nektar Announces New Clinical Collaboration with Merck KGaA Darmstadt, Germany and Pfizer Inc. to Combine NKTR-255, a...
SAN FRANCISCO, Sept. 21, 2021 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) announced it has entered into a new oncology clinical collaboration with Merck KGaA, Darmstadt, Germany and Pfizer Inc. t...
Nektar Therapeutics Stock Performance In The Pandemic vs 2008
We believe that Nektar Therapeutics stock, a biopharmaceutical company focused on discovering and developing medicines in areas that include cancer, autoimmune disease, and chronic pain, is a good buyin...
Nektar (NKTR) Q2 Earnings and Revenues Top, Pipeline On Track
Nektar (NKTR) reports encouraging second-quarter 2021 results. The company remains on track to report top-line data from three registrational studies on bempegaldesleukin in the first half of 2022.
Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates
Nektar (NKTR) delivered earnings and revenue surprises of 4.17% and 7.24%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Nektar Therapeutics Reports Second Quarter 2021 Financial Results
SAN FRANCISCO, Aug. 5, 2021 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported financial results for the second quarter ended June 30, 2021. Cash and investments in marketable securities ...
Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Should You Buy?
Nektar (NKTR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nektar to Announce Financial Results for the Second Quarter 2021 on Thursday, August 5, 2021, After Close of U.S.-Bas...
SAN FRANCISCO, July 27, 2021 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter 2021 on Thursday, August 5, 2021, after the close of U.S.-based...
Nektar Appoints Dimitry S.A. Nuyten, M.D.
SAN FRANCISCO, July 19, 2021 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that it has appointed Dimitry S.A. Nuyten, M.D.
Nektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 42nd Annual Global Healthcare Conference
SAN FRANCISCO, June 7, 2021 /PRNewswire/ -- Nektar Therapeutics' (Nasdaq: NKTR) senior management is scheduled to participate in a virtual fireside chat at the upcoming Goldman Sachs 42nd Annual Global ...
Nektar Therapeutics Announces First Publication of NKTR-358, a Novel Molecule Designed to Selectively Stimulate Expan...
SAN FRANCISCO, May 20, 2021 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the publication of preclinical data in the Journal of Translational Autoimmunity describing NKTR-358, a fir...